港股午後跌幅曾擴至逾200點再尋底騰訊/舜宇/中資保險及藥股領跌
美國製造業PMI疲弱，拖累摩通5月全球製造業PMI重陷收縮報49.8創逾六年半低，加上貿易戰升級，市場憂慮環球經濟衰退。澳洲央行今天議息結果如期近三年首次減息，是繼新西蘭後第二個發達國家減息。滬深股市午後沽盤重現，上證及深成續跌1.1%及1.4%分別報2,858及8,733。
港股五連跌，恆指今早在中移動(00941.HK)及友邦(01299.HK)高開逾1%支撐，高開100點或0.4%報26,994欠承接，掉頭向下，午後跌幅曾擴至221點，低見26,671屢創逾四個月低，現造26,708，續跌184點或近0.7%，但成交額僅602億元。
藍籌股普遍下跌，金融股以中國平安(02318.HK)及國壽(02628.HK)表現最差，股價雙雙失守10天線，報84.35元及17.68元，挫2.5%及2.8%。此外，重磅股騰訊(00700.HK)及舜宇(02382.HK)跌1.9%及2.2%，分別報327.2元及67.2元，齊失守10天線。
內需股旺旺(00151.HK)及吉利(00175.HK)跌逾2%分別報5.65元及12.5元，股價齊失10天線。相反，恆安(01044.HK)及萬洲(00288.HK)反覆逆升1.5%及1.9%，分別報58.75元及6.99元。
創科(00669.HK)跌2%報49.5元，股價失守10天線。此外，金沙(01928.HK)創五個月低，最低見32.8元，現造33.2元，續挫3.2%。
國家財政部聯同醫保局成立工作組稽查77家藥企會計信息真實性，藍籌石藥(01093.HK)及中生製藥(01177.HK)續跌4.3%及2.2%，分別報12.02及7.64元，前者股價創四個半月低。三生製藥(01530.HK)也續跌3.7%報12.14元屢創近期新低。康希諾生物(06185.HK)創上市新低，最低見29.3元，現造29.95元，續挫6.1%。
太古A(00019.HK)反覆續升1.5%報94.45元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
